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Abstract
Mass in ovo vaccination with live attenuated viruses is widely used in the poultry industry to protect against
various infectious diseases. The worldwide outbreaks of low pathogenic and highly pathogenic avian influenza
highlight the pressing need for the development of similar mass vaccination strategies against avian influenza
viruses. We have previously shown that a genetically modified live attenuated avian influenza virus (LAIV) was
amenable for in ovo vaccination and provided optimal protection against H5 HPAI viruses. However, in ovo
vaccination against other subtypes resulted in poor hatchability and, therefore, seemed impractical. In this study,
we modified the H7 and H9 hemagglutinin (HA) proteins by substituting the amino acids at the cleavage site for
those found in the H6 HA subtype. We found that with this modification, a single dose in ovo vaccination of 18-
day old eggs provided complete protection against homologous challenge with low pathogenic virus in ≥70% of
chickens at 2 or 6 weeks post-hatching. Further, inoculation of 19-day old egg embryos with 10
6 EID50 of LAIVs
improved hatchability to ≥90% (equivalent to unvaccinated controls) with similar levels of protection. Our findings
indicate that the strategy of modifying the HA cleavage site combined with the LAIV backbone could be used for
in ovo vaccination against avian influenza. Importantly, with protection conferred as early as 2 weeks post-hatching,
with this strategy birds would be protected prior to or at the time of delivery to a farm or commercial operation.
Introduction
Although depopulation of infected flocks is the method
of choice to control the spread of avian Influenza virus
(AIV) in poultry, vaccination has become an alternative
strategy in order to provide protection to high-risk birds
and reduce the possibility of transmission among birds
and/or to mammals [1,2]. Thus, in many countries in
which avian influenza outbreaks particularly of low
pathogenicity have occurred recurrently, selective culling
followed by vaccination is used as a measure to control
the disease without major economic disruptions. There
are only two types of avian influenza vaccines (AIVs)
licensed worldwide: inactivated whole AIV vaccine and
recombinant fowlpox virus-vectored vaccine expressing
the HA gene of AIV. However, both types of vaccines
have major limitations: inactivated vaccines cannot elicit
strong mucosal and cellular immunity; and previous
exposure to fowlpox virus inhibits the host response to
the fowl-pox vectored vaccine inhibiting anti-influenza
immunity [2-4]. In addition, both strategies are heavily
time-consuming, requiring each bird to be vaccinated
individually by parenteral inoculation.
With the advent of reverse genetics, LAIVs have
emerged as a potential alternative to control avian influ-
enza [5]. Several different strategies have been developed
to attenuate influenza viruses based on mutations in one
or more of the viral internal or surface genes [6-9]. Sev-
eral studies have shown that LAIV vaccines protect
against influenza viruses of low or high pathogenicity in
poultry and mammals. However, field application of
these vaccines is difficult due to the inherent segmented
nature of the influenza genome and the fear that LAIVs
could expand the plethora of influenza viruses through
reassortment. Despite recent reports of the potential
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reassortments, it is unclear how these viruses will
behave under more natural conditions; either by provid-
ing adequate protection or reverting to wild type-like
viruses. Instead, in ovo vaccination using LAIV is an
attractive alternative to provide fast and effective protec-
tion against influenza while avoiding the potential for
reassortment (in ovo vaccination is unlikely to produce
reassortants as other influenza viruses are not present in
the egg).
Several strategies have been developed to generate
LAIVs for in ovo vaccination. A recombinant LAIV was
recently developed that provided immunity against HPAI
H5N1 influenza and Newcastle Disease Virus (NDV)
[7,10]. This recombinant influenza virus expressed the
HA of H5 with a deleted polybasic cleavage site, and the
ectodomain of the hemagglutinin-neuraminidase (HN)
genes NDV instead of NA gene of HPAI H5N1. With
this bivalent virus, a single dose in ovo vaccination of 18-
day-old eggs provided 90% and 80% protection as early as
3 weeks post-hatching, against NDV and HPAI, respec-
tively. A second strategy employed a non-replicating
human adenovirus serotype 5 (Ad5)- vectored vaccine
that expressed the HA of a LPAI H5N9 virus. Similarly,
this vaccine was delivered in ovo and conferred protec-
tion in chickens after challenge with either HPAI H5N1
(89% HA homology; 68% protection) or HPAI H5N2
(94% HA homology; 100% protection) viruses. Unfortu-
nately, in both these studies, the hatchability efficiency
was not addressed in detail [11].
In our previous reports we demonstrated the potential
of a genetically modified LAIV with the internal gene
backbone of A/guinea fowl/Hong Kong/WF10/99
(H9N2) (WF10att) as a vaccine backbone for H5N1
influenza viruses [2]. The WF10att backbone carries
mutations in the PB1 (K391E, E581G and A661T) and
PB2 (N265S) genes. In addition an HA tag was cloned
in frame at the C-terminus of PB1, and enhanced the
att phenotype. This backbone results in virus attenua-
tion in vitro while attaining high viral growth properties
at the permissive temperatures of 33 and 35°C. We also
showed that an H5N1 virus carrying the backbone
ΔH5N1WF10att was amenable for in ovo vaccination
and provided optimal protection against H5 HPAI virus.
More specifically, a single low (10
4 EID50)o rh i g h( 1 0
6
EID50) dose of LAIV resulted in greater than 60% pro-
tection at 4-week post-hatching and 100% protection at
9 to 12-week post-hatching. Incorporation of a boost
regime with either the low or high virus dose at 2-weeks
post-hatching increased the protection efficiency to
100% in 4-week old chickens. The hatchability efficiency
of the high-dose (10
6 EID50) in ovo vaccination was
85%, compared with 90% in low-dose (10
4 EID50)a n d
mock groups [2,12].
In ovo vaccination with live attenuated viruses is
widely used in commercial poultry against various infec-
tious diseases. In ovo vaccination was initially introduced
into the poultry market to protect against Marek’sd i s -
ease virus (MD) [13,14]. Currently, over 80% of US broi-
lers are immunized in ovo with MD vaccine. In ovo
vaccination is also effective and used commercially to
protect poultry from infectious bursal disease virus
(IBDV) [15]. Compared with field vaccination, in ovo
vaccination provides uniform and fast delivery (50,000
egg/h), reduced labor costs, decreased stress to the
birds; and most importantly, elicits early immune
responses, as soon as 2-week post hatching [16]. From
practical and commercial perspectives, in ovo vaccina-
tion not only has to be effective in providing protection
but also has to maintain high hatchability levels (≥90%).
In this report, we investigated the effects of changing
the H7 and H9 cleavage site to that of the LPAI H6
subtype and the timing of vaccination on levels of pro-
tection and hatchability after in ovo vaccination with
LAIV against H7 and H9 LPAI viruses. Our results indi-
cate that in ovo vaccination can result in significant pro-
tection against the H7 and H9 virus subtypes while
maintaining high hatchability (>90%) when the vaccine
is administered in 19-day old chicken embryos.
Materials and methods
Viruses, cells and animals
The influenza virus A/Guinea Fowl/Hong Kong/WF10/
99 (H9N2) (WF10) was kindly provided by Robert Web-
ster from the repository at St. Jude’s Children’s Research
Hospital, Memphis, Tennessee; influenza virus
A/Chicken/Delaware/VIVA/04 (H7N2) (CK/04) was
kindly obtained from Dennis Senne at the National
Veterinary Laboratory Services, USDA, Ames, Iowa. The
viruses were propagated in 10-day-old embryonated spe-
cific-pathogen-free chicken eggs at 35°C and stored at
-70°C. The viruses were titrated by the Reed and
Muench method to determine the 50% egg infectious
dose (EID50) [17]. 293T human embryonic kidney and
Madin-Darby canine kidney (MDCK) cells were main-
tained as described previously [2]. White leghorn chick-
ens (Charles River Laboratories, MA) and Japanese quail
(Murray McMurray Hatchery, Webster, IA) were
hatched at 100°F in a circulating air incubator (G.Q.F.
Manufacturing co. Savannah, GA) and maintained
under BSL2 conditions.
Generation of recombinant virus by reverse genetics
The 6 internal genes of WF10att were described pre-
viously and were used to recover viruses carrying the
surface genes of Ck/04 or WF10 [2]. The cloning of the
Ck/04 surface genes has been previously described [2].
The H7 HA cleavage site, PEKPKPRG, was substituted
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from the H6 HA subtype using a two-step PCR reaction
and the plasmid pDP2002-H7 (Ck/04) as the template
(Figure 1A). In brief, two PCR fragments were produced
by using primers EcoR I 550-F (5’-CTGTCGAATTCA-
GATAATTCAGC-3’) and H7-H6 CVS-R (5’-GGTCTC-
CCGCTGTGGAACATTTCTC-3’), and primers H7-H6
CVS-F (5’-CACAGCGGGAGACCAGAGGCCTTTTTG-
3’) and Pst I 1150-R (5’-GTCAGCTGCAGTTCCCT-
CCCCTTGT-3’). These two fragments were then used
as templates for a new PCR product using primers EcoR
I 550-F and Pst I 1150-R. The fragment was digested
with EcoR I and Pst I, and cloned into pDP-2002-H7
(VIVA/04), to obtain pDP2002-mH7.
The H9 HA cleavage site, PARSSRG, was substituted
with the alternative cleavage site sequence PQIETRG
(Figure 1B) using pDPH9WF10 as the template. Two
PCR fragments were produced by using primers: Xbal I
285-F (5’-CCTCATTCTAGACACATGCAC-3’) and H9-
H6 CVS-R (5’-CCAAATAGTCCTCTAGTTTCGATCT
GAGGCACGTTC-3’), and primers H9-H6 CVS-F (5’-
GAACGTGCCTCAGATCGAAACTAGAGGACTATT
TGG-3’) and EcoN I 1297-R (5’-CCTCATTCTAGACA
CATGCAC-3’). These two fragments were then used as
templates to generate a new PCR fragment using pri-
mers Xbal I 285-F and EcoN I 1297-R. The fragment
was digested with Xbal I and EcoN I, and cloned into
pDPH9WF10, resulting in the formation of pDP-2002-
mH9.
Recombinant viruses were generated using the 8 plas-
mid system in co-cultured 293T and MDCK cells as
described previously [2]. The recombinant viruses
(Table 1) were propagated in 10-day-old embryonated
eggs, titrated by EID50, and stored at -70°C until use.
2mH7N2:6WF10att and 2mH9N2:6WF10att viruses
were sequenced using specific primers, the Big Dye Ter-
minator v3.1 Cycle Sequencing kit (Applied Biosystems,
Foster City, CA), and a 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA), according to the manufac-
turer’s instructions. The genetic stability of mutations
on HA, PB1 and PB2 were evaluated by serial passage of
virus stocks at a 1:10,000 dilution for 10 passages in tri-
plicate samples in 10-day-old embryonated eggs. Viruses
obtained after ten passages were sequenced as described
above.
Hatchability in embryonated chicken eggs
18 or 19-day-old embryonated specific-pathogen-free
chicken eggs were inoculated with either 10
6 or 10
7
EID50 of virus in 0.1 ml inoculum according to the
scheme presented in Table 2. Eggs in the mock group
were inoculated with 0.1 ml of PBS. The egg inoculation
was performed as described previously [2]. Briefly, eggs
were candled, and a small hole was made through the
air cell with an electric drill. Next, 0.1 ml of virus dilu-
tion or PBS was injected into the allantoic cavity using a
21-gauge needle at a depth of 2.5 cm. The percent
hatchability was calculated using the total number of
inoculated eggs versus the number of 21-day old eggs
that hatched in each group. This experiment was per-
formed under BSL-2 conditions according to protocols
approved by the Animal Care and Use Committee of
the University of Maryland.
Plaque assay in chicken embryonic kidney (CEK) cells and
immunostaining
To investigate if the replacement of amino acids at the
HA cleavage site affected the temperature sensitive phe-
notype of the new live-attenuated viruses, plaque assays
were performed in CEK cells at 37°C, 39°C, and 41°C.
Confluent CEK cell monolayers in six-well plates were
infected with 0.5 ml of 10-fold dilutions of virus
2mH7N2:6WF10att or 2H7N2:6WF10att in M199 med-
ium. The cells were incubated with the virus dilutions
for 1 h at 37°C, washed, and overlaid with M199 med-
ium containing 0.9% agar and 0.1 μg/ml TPCK-trypsin.
The plates were then incubated at 37°C, 39°C, and 41°C
with 5% CO2. At 4 days post-inoculation (dpi) the over-
lay was removed and immunostaining was performed as
described previously [2]. In brief, the cells were fixed,
Figure 1 Strategy of modifying the HA cleavage site.( A ) .T h e
substitution of H7N2 (VIVA/04) HA amino acid cleavage site with
alternative cleavage site sequences of H6’s. (B). The substitution of
H9N2 (WF10) HA amino acid cleavage site with alternative cleavage
site sequences of H6’s.
Table 1 Gene constellations of recombinant viruses used
in this study
Virus HA NA Internal genes
(PB1, PB2, PA, NP,
M and NS)
2m2H7N2:6WF10att mH7 (VIVA/04) N2 (VIVA/04) WF10att
2H7N2:6WF10att H7 (VIVA/04) N2 (VIVA/04) WF10att
2mH9N2:6WF10att mH9 (WF10) N2 (WF10) WF10att
2H9N2:6WF10att H9 (WF10) N2 (WF10) WF10att
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(BSA) in PBS. The cells were then incubated with
mouse anti-WF10 monoclonal NP antibody prepared in
our laboratory, followed by incubation with peroxidase-
conjugated goat anti-mouse IgG (Jackson Immuno
Research, West Grove, PA). The presence of viral anti-
gen was revealed by adding several drops of aminoethyl-
carbazol (BD Biosciences, San Diego, CA). The size and
number of plaques at each temperature were compared
to determine the temperature sensitive phenotype of the
new recombinant virus.
Viral replication in MDCK cells
Viral replication was studied to examine the tempera-
ture sensitive phenotype of the new recombinant viruses
in MDCK cells. Confluent monolayers of MDCK cells in
6-well plates were infected with 2m2H7N2:6WF10att or
2H7N2:6WF10att at a MOI = 0.001 and cultured at 35°
C and 39°C, respectively. Supernatant samples were col-
lected at 12, 24, 48, 72, 96 and 120 h post-inoculation,
and the viral titer of these samples was determined by
TCID50 in MDCK cells [2].
Virus replication and transmission in quail
To evaluate the vaccine’s attenuated phenotype in vivo,
2mH7N2:6WF10att was compared to the recombinant
virus 2H7N2:6WF10att. Six 4-week-old Japanese quail
were inoculated by the ocular, intranasal, and intratra-
cheal routes with 10
6 EID50/0.5 ml of either
2mH7N2:6WF10att or 2H7N2:6WF10att vaccine
viruses. Two control quail were inoculated with 0.5 ml
of PBS. At 1 dpi, 3 naïve quail were introduced into the
same isolators, and placed in direct contact with the
inoculated quail to assess virus transmission. At 3 dpi,
3 inoculated quail per group were sacrificed, lungs were
homogenized and virus titers were determined by EID50.
For the remaining quail, tracheal and cloacal swabs were
collected from both the inoculated and direct contact
b i r d sa t1 ,3 ,5 ,7 ,a n d9d p i .T h es w a bs a m p l e sw e r e
stored in glass vials in 1.0 ml freezing Brain Heart Infu-
sion (BHI) medium (BD, Sparks, MD) and titrated for
infectivity in 10-day-old embryonated chicken eggs and
MDCK cells. Sera were collected 2 weeks post-infection
and HA inhibition tests (HI) were performed to quantify
antibodies against HA [18].
Challenge studies
Chickens that hatched after in ovo vaccination were ran-
domly divided into two groups with the same number
of individuals. Early protection was assessed in the first
group of chickens by challenge at 2-weeks post-hatch-
ing. Challenge virus consisted of 5 × 10
5 EID50 of virus
(equal to 500 chicken infectious dose 50 (CID50)) and
was delivered via intranasal inoculation. Late protection
Table 2 Comparison of the hatchability of new recombinant viruses in embryonated chicken eggs vs. the viruses with
wild type HAs and the optimization of the dose and timing for in-ovo vaccination
Vaccine Dose (EID50) Embryo age (Day) % Hatchability (# hatched/total #)
H7N2 (VIVA/04) Vaccine 2mH7N2:6WF10 att 10
6 18 50% (15/30)
(P = 0.016)
10
6 19 93% (42/45)
(P = 0.061)
10
7 19 80% (24/30)
(P = 0.066)
2H7N2:6WF10att 10
6 18 30% (9/30)
10
6 19 43% (13/30)
10
7 19 37% (11/30)
H9N2 (WF10) Vaccine 2mH9N2:6WF10att 10
6 18 63% (19/30)
(P = 0.0161)
10
6 19 90% (27/30)
(P = 0.260)
10
7 19 83% (25/30)
(P = 0.154)
2H9N2:6WF10att 10
6 18 37% (11/30)
10
6 19 60% (18/30)
10
7 19 37% (11/30)
PBS (Mock) 0 18 93% (28/30)
0 19 96% (43/45)
* 3 chickens dead at 2-5 days post-hatching.
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the strategy described above, but in chickens that were
6 weeks old. Tracheal and cloacal swab samples were
collected at 3, 5, and 7 days post-challenge (dpc). Virus
shedding was titrated in MDCK cells by TCID50.S e r a
samples were collected at 2-weeks post-hatching pre-
challenge, and 2 weeks post-challenge. HI titers were
determined as previously described [18]. Animal studies
were conducted under BSL-2 conditions, and performed
according to protocols approved by the Animal Care
and Use Committee of the University of Maryland.
Results
Chicken hatchability is impaired after in ovo vaccination
with H7N2 and H9N2 WF10att viruses
Our previous studies showed that in ovo vaccination with
10
6 EID50 of the ΔH5N1:6WF10att virus resulted in effec-
tive protection against HPAI H5N1 virus [2]. We wanted
to determine whether similar levels of protection could be
obtained against other HA subtypes following the same
strategy. We were particularly interested in the H7 and
the H9 subtypes because they have been responsible for
recurrent outbreaks, particularly in Eurasia (although in
our studies a H7 virus of the North American lineage was
used). Thus, 18-day-old egg embryos were inoculated with
10
6 EID50 of either 2H7N2:6WF10att or 2H9N2:6WF10att
vaccine viruses (Tables 1 and 2). Unfortunately, the hatch-
ability of vaccinated eggs was poor, 30% and 37% in eggs
vaccinated with 2H7N2:6WF10att and 2H9N2:6WF10att,
respectively (Table 2) compared to 85% in eggs vaccinated
with the 2ΔH5N1:6WF10att virus (not shown and [2]).
Chicken hatchability after modification of the HA
cleavage site in H7N2 and H9N2 WF10att viruses
The 2ΔH5N1:6WF10att virus carries the H5 HA protein
from A/Vietnam/1203/04 (H5N1) but its polybasic clea-
vage site, characteristic of HPAI viruses, has been
replaced with that from the LPAI H6 HA virus subtype,
as described in previous reports [19]. In order to deter-
mine if incorporation of the H6 HA cleavage site in the
H7 and H9 subtypes would result in more attenuated
vaccine viruses and improved hatchability, we generated
the recombinant viruses 2mH7N2:6WF10att and
2mH9N2:6WF10att. Modifications at the cleavage site
in these viruses did not have major effects on the in
vitro properties of these viruses. Both recombinant
viruses reached titers of 10
6 TCID50/ml at 120 h post-
infection in MDCK cells inoculated at an MOI = 0.001
a n dc u l t u r e da t3 5 ° C( F i g u r e2a n dd a t an o ts h o w n ) .I n
contrast, viral replication at 39°C was severely restricted,
with viral titers reduced more than 1000-fold relative to
those at 35°C (Figure 2 and data not shown). This indi-
cates that modifications in the HA cleavage site did not
change the temperature sensitive phenotype of these
viruses in MDCK cells. Likewise, plaque assays, per-
formed using CEK cells (Figure 3), showed that
2mH7N2:6WF10att formed significantly smaller plaques
than 2H7N2:6WF10att at 37° and 39°C. As expected,
these viruses were highly restricted at 41°C (yields of
<10
3 PFU/ml) consistent with their att phenotype. Inter-
estingly, the lower virus titers and smaller plaque sizes
of 2mH7N2:6WF10att compared to 2H7N2:6WF10att
indicate an additive effect on attenuation provided by
the modified HA cleavage site. Similar results were
obtained when we compared the 2mH9N2:6WF10att to
2H9N2:6WF10att (not shown). However, despite the
additional attenuation, only a slight improvement in
hatchability (50% and 63%) was observed when 18-day-
old egg embryos were inoculated with 10
6 EID50 of the
2mH7N2:6WF10att and 2mH9N2:6WF10att vaccine
viruses, respectively (Table 2).
Figure 2 Viral replication kinetics of the live-attenuated viruses
in MDCK cells at (A) 35°C and (B) 39°C using MOI of 0.001. Viral
titers at different time points were determined by TCID50.
Figure 3 Plaque morphologies of the live-attenuated viruses in
CEK cell at different temperatures. Confluent CEK cells in six-well
plates were infected with 2mH7N2:6WF10att or 2H7N2:6WF10att.
The numbers 10
-6,1 0
-5, and 10
-3 on the plaque pictures indicate the
virus dilution used to infect cells at the indicated temperature. The
cells incubated at 37°C, 39°C, or 41°C, respectively, for 4 days post
infection and then fixed and the viral antigen was visualized by
immunostaining as described in Materials and Methods. The
plaques sizes were observed and the plaque numbers were
counted and calculated as the log10 PFU/ml, as indicated below the
individual plaque picture. A titer of <3.0 log10 PFU/ml indicates that
no virus was detected at 10
-3 dilution.
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is performed on 19-day old chicken embryos
The previous hatchability results suggested that additional
mutations in the virus genome were required or that the
conditions under which the vaccine was delivered needed
to be changed to improve hatchability. Certainly, addi-
tional mutations in the viral genome could be introduced,
however, they might also affect immunogenicity.
Thus, we chose to deliver the vaccine to 19-day old
chicken embryos and compare hatchability to vaccina-
tion of 18-day old chicken embryos. In ovo vaccination
of 19-day old chicken embryos was performed with
either 10
6 or 10
7 EID50 to explore hatchability efficiency
with two different virus concentrations. Interestingly,
hatchability was greatly improved in 19-day-old vacci-
nated embryos. Hatchability reached 93% and 90% in
the 2mH7N2:6WF10att and 2mH9N2:6WF10att groups,
respectively, when eggs were vaccinated with 10
6 EID50
(Table 2). As shown in Table 2, an increase in virus
delivery dose to 10
7 EID50 was detrimental for hatching.
These results suggest that in ovo vaccination in 19-day
old chicken embryos may be a suitable strategy to gen-
erate an anti-influenza response in chickens.
Modification of the HA cleavage site reduces replication
of 2mH7N2:6WF10att virus in quail
We have previously shown that quail are more suscepti-
ble than chickens to avian influenza viruses. Thus quail
represent a better host to test whether modifications in
our vaccine viruses would have any effect on replication
and transmissibility. To investigate if modification of the
HA cleavage site altered the degree of attenuation and
transmissibility in quail, 2 groups of quail (n = 6) were
inoculated with either the 2mH7N2:6WF10att virus or
the 2H7N2: 6WF10att virus. At 24 h after infection,
3-naïve quail/group were brought in direct contact with
inoculated quail to monitor for transmission (Table 3).
At 3 dpi, 3 inoculated quail from each group were sacri-
ficed to determine virus load in the lungs. No virus was
detected in the lungs of inoculated quail regardless of
the virus used. This finding is consistent with our pre-
vious study showing that the WF10att backbone pre-
vents the virus from replicating in the lower respiratory
tract (not shown and [2,12]). In addition, no virus was
detected in cloacal swabs for any of the quail in the
study (not shown). In contrast, tracheal swabs showed
t h ep r e s e n c eo fv i r u si nt h e2 H 7 N 2 : 6 W F 1 0 att group,
with peak virus titers of 10
2.9 ( a t1d p i )a n d1 0
1.6
TCID50/ml (at 3 dpi) in the inoculated and direct con-
tact quail, respectively. Inoculated quail remained posi-
tive until 5 dpi but were negative by 7 dpi. Only 2 out
of the 3 direct contact quail showed trace amounts of
2H7N2:6WF10att and were negative by 9 dpi. With
r e s p e c tt ot h e2 m H 7 N 2 :6 W F 1 0 att inoculated group,
only trace amounts of virus were observed, and just 1 of
3 quail remained positive by 7 dpi and it became nega-
tive by 9 dpi. Direct contacts in the 2mH7N2: 6WF10att
virus group were negative except for trace amounts of
virus on a single day, 7 dpi, in 2 of the 3 quail. The
levels of virus replication in the different groups corre-
sponded with the levels of seroconversion observed.
Thus, inoculated quail in the 2H7N2:6WF10att group
had the highest neutralizing antibody response, followed
by inoculated quail in the 2mH7N2: 6WF10att group,
whereas the direct contacts in the 2H7N2:6WF10att
showed low, but significant seroconversion. Also consis-
tent with the transient presence of the 2mH7N2:
6WF10att virus in the direct contact group, very low
seroconversion was observed. These studies suggest that
alterations in the HA cleavage site have an effect on
replication in vivo further attenuating these viruses and
limiting the ability to replicate after transmission
(Table 3). We did not perform similar studies in quail
with the H9N2 vaccine viruses. However, we must note
that similar studies in white leghorn chickens did not
result in detectable transmission, when the viruses carry
the att backbone in the context of H7N2 or H9N2 sur-
face genes (not shown).
Stability of new recombinant viruses
The genetic stability of the mutations on HA, PB1,
and PB2, was verified by serial passage of the
2mH7N2:6WF10att and 2mH9N2:6WF10att viruses in
10-day-old embryonated eggs. Amino acids 391E, 581G,
661T and the HA tag on PB1, and 265S on PB2
remained unchanged after serial propagation in eggs.
More importantly, the amino acids at the HA cleavage
site remained unchanged and corresponded to the H6
HA cleavage sequence (PQIETRG).
Single dose in ovo vaccination provides protection in
chickens from homologous challenge with H7 and H9
LPAI viruses at 2 and 6 weeks post-hatching
To further evaluate whether in ovo immunization would
result in protection against H7 or H9 viruses, vaccinated
chickens were divided into two groups, and subse-
quently challenged with homologous virus at either 2 or
6 weeks post-hatching (Tables 4 and 5).
Pre-challenge sera collected at 2 weeks post-hatching
showed limited seroconversion in chickens that received
the 2mH7N2:6WF10att (Table 4), both in terms of the
number of seropositive chickens as well as the level of
HI responses. However, sera c o l l e c t e da t6w e e k sp o s t -
hatching showed increased numbers of seropositive
chickens and increased HI titers (Table 4). Relative to
2mH7N2:6WF10att, improved and more consistent anti-
body responses were obtained in chickens that were vac-
cinated with 2mH9N2:6WF10att (Table 5). In terms of
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Page 6 of 10protection, significant protection was observed in chick-
ens challenged with 500 CID50 of Ck/04 (H7N2) at 2 or
6 weeks post-hatching but only in the 19-day old
embryo vaccinated groups. Tracheal virus shedding was
d e t e c t e di no n l y2o u t8a n d1o u to f5c h i c k e n si nt h e
19-day old embryo groups that received 10
6 or 10
7
EID50, respectively, of 2mH7N2:6WF10att.T h e r ew a s
also a sharp decrease in cloacal virus shedding in these
groups, with just 1 out 8 (10
6 EID50 group) and 1 out
5( 1 0
7 EID50 group) virus positive chickens and only at
7 dpc (Table 4). In contrast, in the 18-day old embryo
vaccinated group only 1 out 4 and 2 out 4, at 2 and
6 weeks post-hatching, respectively, showed protection
and no detectable virus replication. Similar protective
responses were observed in the WF10(H9N2) challenged
chickens. Chickens in the 19-day old embryo vaccinated
groups showing the best protection, and those in the
18-day old embryo vaccinated groups showed the
decreased protection (Table 5). Significant seroconver-
sion in all the groups at 14 dpc indicated that lack of
virus shedding in protected chickens was not due to a
failure in our challenge approach. Considering the 10
6
EID50 vaccine dose in the 19-day old embryo vaccinated
groups for both att vaccines, there was between 70 and
80% protection efficiency in chickens challenge at 2 or
6 weeks post-hatching, respectively. Slightly better pro-
tection efficiency (82%) was observed in the 10
7 EID50
vaccine dose groups; however, it was achieved at the
expense of lower hatchability rates (~91% for the 10
6
EID50 versus ~80% for the 10
7 EID50 groups). In con-
trast, an average of only 55% protection efficiency was
observed in the groups vaccinated with a dose 10
6 EID50
in 18-day old embryos.
Discussion
The HA is perhaps the most important protein in influ-
enza viruses, as it is a critical determinant of host range
and virulence [20,21]. The HA protein, encoded in seg-
ment 4, is expressed on the virus surface as homotri-
mers. It is initially produced as a precursor, HA0, that
requires post-translational modifications, including clea-
vage and glycosylation in order to become fully active
[22]. Cleavage of the HA0 precursor leads to two subu-
nits, HA1 - N-proximal - and HA2 - C-proximal -,
which are maintained covalently linked via disulfide
bonds. Trypsin-like host proteases found in the lumen
of the respiratory and intestinal tracts are involved in
the cleavage of the HA of low pathogenic avian influ-
enza viruses - LPAIV - (and mammalian influenza
viruses) [22]. Intracellular furin-like proteases have been
Table 3 Replication and transmission study of recombinant virus 2H7N2:6WF10att and 2mH7N2:6WF10att in quail
Virus Group # of positive tracheal swab/total # post-inoculation
(log10TCID50/ml ± SD) at peak viral shedding
# of seroconverted/total #
(Average HI titer at 14 dpi)
1 dpi 3 dpi 5dpi 7 dpi 9 dpi
2H7N2:6WF10att Inoculated 6/6 (2.9 ± 0.4) 6/6* 3/3 0/3 0/3 3/3 (133)
Contact NA 3/3 (1.6 ± 1.4) 3/3 2/3 0/3 3/3 (47)
2mH7N2:6WF10att Inoculated 6/6 (<0.7) 6/6* 1/3 1/3 0/3 3/3 (87)
Contact NA 0/3 0/3 2/3 (<0.7) 0/3 2/3 (10)
* 3 quail from each inoculated group were sacrificed at 3 dpi to determine virus load in the lungs.
Table 4 Single-dose 2mH7N2:6WF10att in-ovo vaccination study in chickens challenged with low-pathogenic H7N2
(Ck/04) at 2 and 6 weeks post-hatching
Vaccine
dose (EID50)/
embryo
age (days)
# positive
HI/total #
pre-challenge
(HI titer)
Age
(in weeks)
at time of
challenge
# Shedding virus/total # in swabs
(log10TCID50/ml ± SD)
# positive
HI/total
#a t
14 dpi
Tracheal Cloacal
3 dpc 5 dpc 7 dpc 3 dpc 5 dpc 7 dpc
0 (Mock) 0/8 2 8/8 (3.4 ± 0.8) 8/8 (2.9 ± 0.6) 0/8 2/8 (3.7) 5/8 (3.4 ± 0.2) 5/8 (3.2 ± 0.5) 8/8 (170)
10
6, 18 1/4 (3) 2 3/4 (3.3 ± 1.0) 3/4 (2.9 ± 0.9) 0/4 2/4 (4.5 ± 0.7) 3/4 (3.7 ± 1.0) 3/4 (3.7 ± 0.7) 4/4 (320)
10
6, 19 6/8 (13) 2 2/8 (3.5 ± 0.7) 1/8 (2.3) 0/8 0/8 0/8 1/8 (2.0) 8/8 (240)
10
7, 19 3/5 (5) 2 1/5 (2.7) 0/5 0/5 0/5 0/5 1/5 (2.3) 5/5 (272)
0 (Mock) 0/7 6 7/7 (3.5 ± 0.7) 7/7 (3.4 ± 0.7) 0/7 3/7 (3.9 ± 0.5) 5/7 (3.7 ± 1.0) 5/7 (3.3 ± 0.8) 7/7 (525)
10
6, 18 2/4 (50) 6 2/4 (4.1 ± 0.6) 2/4 (3.9 ± 0.6) 0/4 1/4 (3.5) 2/4 (4.3 ± 0.4) 2/4 (3.6 ± 0.1) 4/4 (360)
10
6, 19 5/7 (51) 6 2/7 (3.4 ± 0.2) 0/7 0/7 1/7 (3.7) 1/7 (3.5) 1/7 (3.3) 7/7 (525)
10
7, 19 4/5 (64) 6 1/5 (3.7) 1/5 (3.7) 0/5 0/5 0/5 0/5 5/5 (640)
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genic avian influenza viruses - HPAIV [22]. The number
of basic amino acid residues preceding the cleavage site
determines recognition by eith e rt r y p s i n - l i k eo rf u r i n -
like proteases, with a string of basic amino acids allow-
ing the latter to cause intracellular maturation of the
HA at the level of the endoplasmic reticulum [23].
Furin-like protease cleavage produces mature virions
that can spread cell to cell without having to reach the
lumen of the respiratory or intestinal tracts. This per-
mits the development of a fatal systemic infection,
hence the so-called highly pathogenic influenza. There-
fore, the cleavability of HA is one of the critical factors
for viral tissue tropism and pathogenicity [24,25]. In this
study, we modified the cleavage site of the influenza
virus H7 and H9 HA protein genes to encode sequences
corresponding to the H6 HA cleavage site (mH7 and
mH9) in order to improve hatchability after in ovo vac-
cination. It has been previously shown that the H6 HA
cleavage site can transform a HPAIV of the H5N1 sub-
type into a LPAIV [19]. We have previously shown that
a LPAI H5N1 virus carrying att mutations is amenable
for in ovo vaccination resulting in ≥60% protection
while maintaining at least 85% hatchability [2]. In this
study we sought to examine whether the mH7 and mH9
att viruses viruses showed similar replication yields as
unmodified H7 and H9 att viruses, and if these modified
viruses were more amenable for in ovo vaccination with-
out decreased immunogenicity. Growth kinetic studies
in tissue culture cells showed similar yields for the mH7
compared to the unmodified H7 viruses (Figure 2) and
similar results were obtained comparing the mH9 with
the unmodified H9 pairs (not shown). As the safe “win-
dow” for in ovo vaccination of chicken embryos is
between day 17 at 12-14 hours to day 19 at 2-4 hours
[26], we chose days 18 and 19 for vaccination to test the
effects on hatchability of the att vaccines. Hatchability
studies clearly demonstrated that the mH7 and mH9 att
viruses allowed for hatchability (90-93%, 19-day old
embryos) similar to the PBS inoculated controls
(93-96%), which were much higher than those obtained
with the unmodified H7 or H9 att viruses (43-60%,
19-day old embryos). We found that the combination of
the modified HA cleavage site, vaccine dose, and time of
vaccine delivery, had a significant impact on hatchability
rates. Thus, 18-day old chicken embryos vaccinated with
the mH7 or the mH9 att viruses showed improved
hatchability rates compared to the unmodified HA att
counterparts, but they were significantly lower than the
rates obtained after vaccinating 19-day old embryos
(Table 2). Likewise, increasing the dose to 10
7 EID50 of
either mH7 or mH9 att viruses resulted in 10% hatch-
ability loss compared to the same age embryos inocu-
lated with 10
6 EID50 of the same viruses.
We speculate that the introduction of the alternative
H6 HA cleavage site in the mH7 and mH9 att viruses
(and perhaps in the ΔH5 att virus) leads to reduced HA
cleavage efficiency and, thus, these viruses exhibit
growth restrictions at higher temperatures in vitro (Fig-
ure 3) and in vivo in 18-19-day old chicken embryos
(Table 2). However, these viruses showed no defects in
terms of virus yield at the permissive temperatures of 33
and 35°C in tissue culture (Figure 2) or in 10-day old
chicken embryos. These characteristics are important
because efficient immunogenicity was maintained with-
out sacrificing virus yield. In fact, 2mH7N2:6WF10att
and 2mH9N2:6WF10att viruses can easily achieve titers
on the order of 10
8 EID50/ml when grown in 10-day old
embryonated chicken eggs (data not show), thus making
them ideal for mass production.
In ovo vaccination is an attractive approach for vacci-
nation of chickens, particularly broilers [26,27]. It helps
to ‘close the window’ of susceptibility between vaccina-
tion and early exposure to infectious agents compared
with post-hatch vaccination [27]. Because chickens
already develop certain immunologic functions before
Table 5 Single-dose 2mH9N2:6WF10att in-ovo vaccination study in chickens challenged with low-pathogenic H9N2
(WF10) at 2 and 6 weeks post-hatching
Vaccine dose
(EID50)/embryo age (days)
# positive HI/total
# before challenge
Age (in weeks) at
time of challenge
# Shedding virus/total # in swabs (log10TCID50/ml ± SD)
Tracheal # positive HI/total # at 14 dpi
3 dpc 5 dpc 7 dpc
0 (Mock) 0/7 2 7/7 (2.7 ± 0.6) 7/7 (2.5 ± 0.3) 0/7 7/7 (217)
10
6, 18 3/5 (14) 2 2/5 (2.2 ± 0.2) 2/5 (2.3 ± 0.4) 0/5 5/5 (192)
10
6, 19 6/7 (32) 2 1/7 (2.5) 0/7 0/7 7/7 (286)
10
7, 19 3/4 (32) 2 1/4 (2.3) 0/4 0/4 4/4 (260)
0 (Mock) 0/7 6 7/7 (2.5 ± 0.3) 7/7 (2.5 ± 0.2) 0/7 7/7 (320)
10
6, 18 2/5 (30) 6 3/5 (2.6 ± 0.7) 3/5 (2.2 ± 0.9) 0/5 5/5 (224)
10
6, 19 5/7 (71) 6 2/7 (2.4 ± 0.5) 0/7 0/7 7/7 (446)
10
7, 19 3/3 (67) 6 0/3 0/3 0/3 3/3 (227)
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Page 8 of 10hatching, in ovo vaccination stimulates both the innate
and adaptive immune responses. Thus, in ovo vaccinated
chicks develop an appreciable degree of protection by
the time of hatching [27]. This indeed appears to be the
case since in our approach chickens showed significant
protection (≥ 70%) when challenged as early as 2 weeks
post-hatching. It is tempting to speculate that under
industrial settings higher protection efficiencies could be
obtained since automated systems would result in more
accurate, controlled and efficient administration of the
vaccine compared to our manual approach. In addition,
because the mH7 and mH9 att viruses are more attenu-
ated in vivo than the unmodified att counterparts, we
further speculate that these HA genes are not likely to
outcompete wild type influenza viruses through reas-
sortment, and thus, should be safe to use in the field.
The unprecedented spread of low pathogenic H7 and
H9 influenza viruses in commercial settings, calls for the
implementation of alternative prevention and control
strategies. Our report provides for a viable alternative to
the classical vaccination approaches against avian
influenza.
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